

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

VON DER KAMMER *et al.*

Appl. No.: 10/520,065 (*U.S. Nat'l Phase of PCT/EP03/07173*)

I.A. Filing Date: July 4, 2003

For: **Diagnostic and Therapeutic Use of  
TB2 Gene and Protein for  
Neurodegenerative Diseases**

Confirmation No.: 5124

Art Unit: *To be assigned*

Examiner: *To be assigned*

Atty. Docket: 2335.0040001/SRL/KPQ

**Second Preliminary Amendment and Submission of Sequence Listing**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Notification of Missing Requirements Under 35 U.S.C. § 371 in the United States Designated/Elected Office (DO/EO/US) of Application, dated July 13, 2005, in the above identified matter, and in advance of prosecution, please amend the application as follows:

***In the Specification:***

Please insert the sequence listing at the end of the application.

Please substitute the paragraph appearing at page 31, line 19, with the following paragraph:

First, a standard curve was generated to determine the efficiency of the PCR with specific primers for human TB2 (5'-CGAGTCCCAGATGGACAGTGT-3' (SEQ ID NO. 3) and 5'-GTGATGGCATCTGCAGTCTCTT-3' (SEQ ID NO. 4)). PCR amplification (95 °C and 1 sec, 56 °C and 5 sec, and 72 °C and 5 sec) was performed in a volume of 20